Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
CD20 CD3 双特异性抗体 TCE 治疗自免 - 礼进生物
CD3 x BCMA BISPECIFICS
Gene editing of CD3 epsilon to redirect regulatory T cells for adoptive ...
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in ...
First-in-Class Claudin18.2/CD3 TCE Enters Phase III Trials for ...
We develop a TCE platform with anti-TCR/CD3 nanobodies, instead of ...
2: The TCR structure, comparison and the CD3 complex: In this picture ...
CD3 Proteins – KACTUS
TCR-CD3复合物 | 破局 CD3 抗体开发，驱动TCE双抗创新|TED|自身免疫性疾病|细胞|免疫|靶向_新浪新闻
A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with ...
Effect of CD3 binding affinity Kd (CD3-TCE) on biTTC and moTTC density ...
【TCE双抗专题系列报告】：创新药两年内的赛道性投资机会——TCE 双抗赛道(1)【国盛医... 1 TCE 双抗是什么? TCE 双抗是一类 ...
Illustration of bi-specific TCE (BiTE) and tri-specific TCE (TriTE ...
Biocytogen's DLL3×CD3×4-1BB TriAb: A New Path for TCE Therapies ...
Accelerating TCE Drug Development with Humanized Mouse Models_GemPharmatech
A Review of T Cell Markers, CD3 Antigens and Antibodies - Creative ...
Alnuctamab, a BCMA x CD3 TCE, in the treatment of multiple myeloma ...
CD3 × CD28 cross-interacting bispecific antibodies improve tumor cell ...
Precision-Engineered CD3 T-Cell Engagers for Solid Tumours: Conditional ...
既可独自美丽，也可团队合作的CD3_同立海源il7-CSDN博客
Overcoming the challenges associated with CD3+ T-cell redirection in ...
小禾说 | 自身免疫疾病靶点与模型系列(16)——CD3-TCE爆火，自免双抗/多抗疗法进入新阶段 - 知乎
CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond ...
B7-H6/CD3 T-cell engager | InOncology – Boehringer Ingelheim
T细胞衔接器双抗(TCE)的作用机制及其药物在肿瘤治疗中的应用_生物器材网
双特异性T细胞衔接器（TCE）-CD3双抗-TCE作用机制/技术平台-德泰生物
T-Cell Engagers—The Structure and Functional Principle and Application ...
CD3单克隆抗体：突破性疗法的又一次“浴火重生”_细胞_异源_信号
Selected signalling proteins recruited to the T‐cell receptor–CD3 ...
T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update
CD3亲和力微调：抗肿瘤活性与安全性之间的理想平衡-TCE研发-德泰生物
1068 ATG-107, a novel 2+1 CD3-based T cell engager (TCE) targeting FLT3 ...
【AACR 2025】上细前沿突破四 | TCE核心平台：基于抗CD3与肿瘤特异性靶点的纳米抗体库为精准免疫治疗提供核心工具医药新闻 ...
B7-H6/CD3 T-cell Engager Results | InOncology – Boehringer Ingelheim
CD3双抗设计考量因素及国内项目梳理 - 知乎
Molecular Construction of T Cell Engagers: Formats Matter
【AACR 2025】上细前沿突破四 | TCE核心平台：基于抗CD3与肿瘤特异性靶点的纳米抗体库为精准免疫治疗提供核心工具
你了解CD3双抗开发中的“坑”吗？ - 企业动态 - 丁香通
文献分享：一种新型T细胞衔接器双特异性抗体
CD3/CD19/BCMA 从肿瘤免疫到自身免疫性疾病的多面利器 - 知乎
[InvivoGen] T cell의 CD3과 CD28을 동시에 결합하는 Bispecific antibody CD3-CD28 ...
ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager ...
1191 ATG-021, a novel 2+1 CD3-based T cell engager (TCE) targeting ...
T淋巴细胞表面关键分子：CD3（内含CD3抗体序列下载）_cd3抗体结构-CSDN博客
GRAPHIC
靶点荟萃 | CD3：TCE双抗/多抗的黄金靶点-技术前沿-资讯-生物在线
突破：首个实体瘤TCE双抗获批上市 今日，Amgen宣布，FDA加速批准其靶向DLL3/CD3的双特异抗体tarlatamab上市，用于治疗 ...
Crystal structure of the human T cell receptor CD3εγ heterodimer ...
1.7亿美元首付：第一三共从默沙东引进一款DLL3/CD3双抗医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
DLL3/CD3 T-cell engager | InOncology – Boehringer Ingelheim
In vivo efficacy of LY6G6D/CD3 TcE. (A-C) Anti-tumor activity of ...
Frontiers | T-cell virtuosity in ‘‘knowing thyself”
T细胞衔接器(TCEs)的作用机制、分类、及TCE药物研发概览_生物器材网
Ionic CD3−Lck interaction regulates the initiation of T-cell receptor ...
Cancers | Free Full-Text | A Novel Bispecific T-Cell Engager (CD1a x ...
TCE三抗///CD3/CD2/ULBP2/5/6三抗///鳞状肿瘤临床前疗效 - 知乎
Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer ...
JNJ-78306358, a first-in-class bispecific T cell engaging antibody ...
下一代TCE之精准激活T细胞亚群医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Bispecific T Cell Engagers and Synthetic Immunity: Circumventing Immune ...
登顶Nature子刊，下一代in vivo TCE疗法杀出“中国黑马”
CD3蛋白：TCE药物开发的核心引擎-技术资料-杭州斯达特生物科技有限公司
Innovations in cancer immunotherapy: Bi-specific T cell engagers | CAS
Frontiers | Trispecific eFab-eIg T-cell engagers targeting HER2 and HER3
T-cell engager CD3ε | Highlighted Client Publication | genOway
CD3ε抗体如何成为解析T细胞激活与调控的核心工具？_t细胞受体复合体cd3ε亚基-CSDN博客
CD3蛋白助力突破TCE開發瓶頸
做双抗研发的你确定使用的CD3蛋白是1:1异源二聚体吗？-公司新闻-北京百普赛斯生物科技股份有限公司
FDA整治药企拖延症，暂缓第四款CD3×CD20双抗上市 - 知乎
实体瘤TCE时代开启 Armstrong 2025年1月9日， Vir Biotechnology 公布了前抗体实体瘤TCE的最新临床数据 ...
新一代 T 细胞接合剂 (T-cell engagers,TCE)丨Glofitamab,罗氏CD20/CD3双特异性抗体医药新闻 ...
DLL3：多赛道进击小细胞肺癌 - 知乎
CD3蛋白：高生物活性经抗体结合验证，赋能TCE药物开发-公司新闻-北京百普赛斯生物科技股份有限公司
菲鹏制药研发具备种属交叉活性抗CD3纳米抗体，引领TCE药物开发新方向医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Masking bispecific T cell engagers until they reach the tumor improves ...
